Bolt Projects Holdings Soars 109.34% on Royalty Pharma Partnership

Bolt Projects Holdings, Inc. shares skyrocketed by 109.34% in pre-market trading on September 4, 2025, marking a significant surge in investor interest and market sentiment.

This dramatic rise can be attributed to the recent partnership between Royalty Pharma and Zenas BioPharma, which aims to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease. Royalty Pharma's commitment to provide up to $300 million in funding, in exchange for a royalty on sales of obexelimab, has been well-received by investors, reflecting positively on Bolt Projects Holdings, Inc.

This strategic collaboration not only highlights the potential of obexelimab in the medical field but also underscores the financial backing and market confidence in Zenas BioPharma's innovative treatments. The partnership is expected to drive significant growth and development for both companies, further bolstering investor optimism in the sector.